Loading...
ISEE logo

IVERIC bio, Inc.NasdaqGS:ISEE Stock Report

Market Cap US$5.5b
Share Price
n/a
1Y236.3%
7D0.9%
1D0.4%
Portfolio Value
​
View

IVERIC bio, Inc.

NasdaqGS:ISEE Stock Report

Market Cap: US$5.5b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

IVERIC bio (ISEE) Stock Overview

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. More details

ISEE fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Trading at 68.2% below our estimate of its fair value

Earnings are forecast to grow 59.04% per year

Risk Analysis

Makes less than USD$1m in revenue ($0)

Shareholders have been diluted in the past year


ISEE Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW440,641 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
440,641 investors already sharing narratives
View all narratives

IVERIC bio, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for IVERIC bio
Historical stock prices
Current Share PriceUS$39.95
52 Week HighUS$39.99
52 Week LowUS$9.39
Beta1.1
1 Month Change4.91%
3 Month Change39.10%
1 Year Change236.28%
3 Year Change791.74%
5 Year Change1,413.26%
Change since IPO51.90%

Recent News & Updates

Recent updates

Seeking Alpha • Sep 06

Iveric drives Apellis lower as Street reacts to Phase 3 data for GA candidate

Iveric bio (NASDAQ:ISEE), have sparked volatility in rival biotechs on Tuesday after the clinical-stage company announced results from a Phase 3 trial for Zimura involving patients with eye disease geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). ISEE said that the second late-stage trial for the candidate reached the primary goal, and it would submit a new drug application for Zimura by the end of Q1 2023. While ISEE added over 63%, Apellis Pharmaceuticals (APLS) and NGM Biopharmaceuticals (NGM), both of which have clinical stage candidates targeted at GA, have lost more than 7% and gained nearly ~6%, respectively, in reaction. With an Outperform rating on the stock, Cowen raised its price target on ISEE to $30 from $25 per share and argued that Zimura “has demonstrated efficacy in line with Apellis’s recent studies, while safety appears better.” Last month, APLS shares dipped in reaction to 24-month data for its lead asset pegcetacoplan from two Phase 3 trials involving patients with GA secondary to AMD. In contrast, B. Riley called the data “highly anticipated, yet disappointing” and downgraded the stock to Sell from Neutral, slashing the price target to $8 from $12 per share. The results represent “the best case scenario” for NGM’s trial in GA, the analyst added, NGM is on track to report topline data from a Phase 2 trial for its GA candidate NGM621 in Q4 2022.
Seeking Alpha • Jul 25

IVERIC bio Q2 2022 Earnings Preview

IVERIC bio (NASDAQ:ISEE) is scheduled to announce Q2 earnings results on Monday, July 25th, after market close. The consensus EPS estimate is -$0.30. Over the last 3 months, EPS estimates have seen 3 upward revisions and 1 downward revision.
Seeking Alpha • Jul 05

Iveric bio pay DelSiTech €1.25M upfront to develop new formulations of eye disorder drug Zimura

Iveric bio (NASDAQ:ISEE) signed a license agreement for the right to develop and commercialize new formulations of eye disorder drug candidate Zimura using DelSiTech's silica-based sustained release technology. Under the agreement, Iveric will pay DelSiTech €1.25M upfront and development and commercial milestones plus royalties on net sales of products. Iveric said that as part of its lifecycle expansion plan for Zimura, it is committed to developing sustained release technologies to treat age-related macular degeneration (AMD) and that these technologies could potentially address patients being treated for geographic atrophy (GA) and intermediate AMD. Iveric said it expects data from a second phase 3 trial, dubbed GATHER2, of Zimura for GA in Q3 2022 and if results are positive it will file for U.S. and EU approval of of Zimura for GA. The study called GATHER1 had already met its main efficacy goal, according to the company. The company also plans to explore Zimura in earlier stages of AMD by starting a trial evaluating the current formulation of Zimura in patients with intermediate AMD in Q4 2022. ISEE +1.49% to $9.54 premarket July 5
Seeking Alpha • Jun 23

IVERIC bio: A First Take

Today, we take our first look at ocular focused biotech IVERIC bio, Inc. The stock has seen some insider buying here in June and its primary asset Zumira seems on the path to commercialization. An investment analysis follows in the paragraphs below.
Seeking Alpha • Sep 16

Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field

Iveric Bio is developing Zimura - indicated for Geographic Atrophy - an eye disease that often leads to blindness. Zimura has met its primary endpoint in a pivotal Phase 3 trial, and data from a fully enrolled second Phase 3 will be available in H222. Zimura's chief rival Pegcetacoplan, developed by Apellis, recently missed one primary endpoint and met another in its 2 Phase 3 trials in GA. That has opened the door for Zimura to become the first drug ever approved for GA - a multi-billion dollar market. Iveric is aiming to create a franchise with Zimura, targeting all forms of advanced macular degeneration. Everything hangs on the outcome of its second pivotal trial.

Shareholder Returns

ISEEUS BiotechsUS Market
7D0.9%-5.2%-0.9%
1Y236.3%37.6%14.2%

Return vs Industry: ISEE exceeded the US Biotechs industry which returned -4.2% over the past year.

Return vs Market: ISEE exceeded the US Market which returned 14.1% over the past year.

Price Volatility

Is ISEE's price volatile compared to industry and market?
ISEE volatility
ISEE Average Weekly Movement5.4%
Biotechs Industry Average Movement9.5%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: ISEE's share price has been volatile over the past 3 months.

Volatility Over Time: ISEE's weekly volatility has decreased from 13% to 5% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007163Glenn Sblendorioivericbio.com

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases.

IVERIC bio, Inc. Fundamentals Summary

How do IVERIC bio's earnings and revenue compare to its market cap?
ISEE fundamental statistics
Market capUS$5.51b
Earnings (TTM)-US$222.90m
Revenue (TTM)n/a
0.0x
P/S Ratio
-24.7x
P/E Ratio

Is ISEE overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ISEE income statement (TTM)
RevenueUS$0
Cost of RevenueUS$136.54m
Gross Profit-US$136.54m
Other ExpensesUS$86.37m
Earnings-US$222.90m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.62
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio20.3%

How did ISEE perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/07/12 06:19
End of Day Share Price 2023/07/10 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IVERIC bio, Inc. is covered by 14 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yuan ZhiB. Riley Securities, Inc.
Ling WangBTIG
Gbolahan Amusa BenzChardan Capital Markets, LLC